Premature myocardial infarction as the initial manifestation of JAK2 positive polycythemia vera in a young adult: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261359Keywords:
Polycythemia vera, JAK2 mutation, Myocardial infarction, Premature thrombosis, Myeloproliferative neoplasm, SplenomegalyAbstract
Polycythemia vera is a clonal myeloproliferative neoplasm characterized by erythrocytosis and commonly associated with leukocytosis, thrombocytosis, and splenomegaly. Activating mutations in the JAK2 gene play a central role in its pathogenesis. Although typically a disease of older adults, polycythemia vera may present at a younger age with atypical and severe manifestations. We report the case of a 37-year-old Indian male who presented with massive splenomegaly and abnormal blood counts. Notably, the patient had a prior history of premature myocardial infarction requiring percutaneous coronary intervention at a young age, in the absence of conventional cardiovascular risk factors. Current evaluation revealed erythrocytosis, leukocytosis, thrombocytosis, and panmyelosis on bone marrow examination. Molecular testing confirmed the presence of a JAK2 mutation, establishing the diagnosis of polycythemia vera. The earlier myocardial infarction was retrospectively attributed to the underlying prothrombotic state associated with the disease. This case highlights that polycythemia vera may initially manifest as premature arterial thrombosis in young individuals. Awareness of such presentations is essential, as early diagnosis and appropriate management can prevent recurrent thrombotic complications and disease progression.
References
Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2019;134(4):341-51.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in India. Indian J Hematol Blood Transfus. 2016;32(2):204-9.
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Blood. 2011;118(12):3219-27.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Haematologica. 2011;96(3):417-23.
Chatterjee T, Choudhry VP, Saxena R. Clinical and hematological profile of polycythemia vera in Eastern India. Asian J Transfus Sci. 2018;12(2):125-30.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
Verstovsek S. Management of complications in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2015;2015:340-7.
McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2020;42(Suppl 1):41-8.
Ghosh K, Shetty S, Jijina F. Myeloproliferative neoplasms in India: diagnostic and therapeutic challenges. Indian J Med Res. 2019;149(4):421-9.
Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Julià A, Hernández-Boluda JC, et al. Essential thrombocythemia and polycythemia vera in young individuals: frequency and clinical implications. Ann Hematol. 2012;91(1):77-81.
Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-84.
Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Hematology Am Soc Hematol Educ Program. 2017;2017:470-9.
Vannucchi AM. How I treat polycythemia vera. Blood. 2014;124(22):3212-20.
Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 2009;94(1):7-10.
Barbui T. Thrombosis in polycythemia vera: pathogenesis and prevention. Haematologica. 2020;105(1):35-45.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(3):379-98.
McMullin MF. Diagnosis and management of polycythemia vera: a European perspective. Haematologica. 2022;107(1):19-34.